Cellavision Ab Stock Current Liabilities
| CEVI Stock | SEK 221.50 4.50 2.07% |
CellaVision AB fundamentals help investors to digest information that contributes to CellaVision's financial success or failures. It also enables traders to predict the movement of CellaVision Stock. The fundamental analysis module provides a way to measure CellaVision's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CellaVision stock.
CellaVision |
CellaVision AB Company Current Liabilities Analysis
CellaVision's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current CellaVision Current Liabilities | 40 M |
Most of CellaVision's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CellaVision AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, CellaVision AB has a Current Liabilities of 40 M. This is 97.72% lower than that of the Health Care Equipment & Supplies sector and 92.45% lower than that of the Health Care industry. The current liabilities for all Sweden stocks is 99.49% higher than that of the company.
CellaVision Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CellaVision's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CellaVision could also be used in its relative valuation, which is a method of valuing CellaVision by comparing valuation metrics of similar companies.CellaVision is currently under evaluation in current liabilities category among its peers.
CellaVision Fundamentals
| Return On Equity | 0.2 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 6.21 B | |||
| Shares Outstanding | 23.85 M | |||
| Shares Owned By Insiders | 38.15 % | |||
| Shares Owned By Institutions | 43.00 % | |||
| Price To Earning | 90.85 X | |||
| Price To Book | 10.18 X | |||
| Price To Sales | 9.60 X | |||
| Revenue | 565.55 M | |||
| Gross Profit | 438.32 M | |||
| EBITDA | 193.6 M | |||
| Net Income | 158.3 M | |||
| Cash And Equivalents | 190.2 M | |||
| Cash Per Share | 7.97 X | |||
| Total Debt | 95.84 M | |||
| Debt To Equity | 9.10 % | |||
| Current Ratio | 4.12 X | |||
| Book Value Per Share | 26.90 X | |||
| Cash Flow From Operations | 159.72 M | |||
| Earnings Per Share | 5.27 X | |||
| Target Price | 246.67 | |||
| Number Of Employees | 235 | |||
| Beta | 1.07 | |||
| Market Capitalization | 5.21 B | |||
| Total Asset | 825.21 M | |||
| Working Capital | 155 M | |||
| Current Asset | 195 M | |||
| Current Liabilities | 40 M | |||
| Z Score | 32.4 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 1.30 % | |||
| Net Asset | 825.21 M | |||
| Last Dividend Paid | 2.25 |
About CellaVision Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CellaVision AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CellaVision using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CellaVision AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for CellaVision Stock Analysis
When running CellaVision's price analysis, check to measure CellaVision's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CellaVision is operating at the current time. Most of CellaVision's value examination focuses on studying past and present price action to predict the probability of CellaVision's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CellaVision's price. Additionally, you may evaluate how the addition of CellaVision to your portfolios can decrease your overall portfolio volatility.